Arcutis Biotherapeutics, Inc. (ARQT) Stock Price & How to Invest

Arcutis Biotherapeutics is a commercial-stage biopharmaceutical company focused on medical dermatology. Its business is built around ZORYVE, a topical formulation of roflumilast that inhibits phosphodiesterase type 4 (PDE4), an anti-inflammatory target long used in dermatology. ZORYVE is sold as a cream 0.3% for plaque psoriasis, a foam 0.3% for seborrheic dermatitis, and cream formulations (0.15% and 0.05%) for atopic dermatitis spanning adults down to young children. The pitch to dermatologists is a steroid-free, once-daily topical with a clean tolerability profile that can be used on sensitive and intertriginous skin, and the company markets it as the leading branded topical across those three inflammatory skin conditions combined.

The investment picture is a classic single-franchise growth story reaching an inflection. ZORYVE net product sales grew to about $372 million in 2025, up roughly 123% year over year, and Arcutis posted its first profitable quarter in Q4 2025 with positive operating cash flow before guiding 2026 revenue to roughly $480 to $495 million. Because nearly all revenue comes from one molecule, the stock is highly sensitive to prescription momentum, payer coverage, gross-to-net pricing dynamics, and new-indication approvals (including pediatric and infant atopic dermatitis expansions). Profitability is not yet consistent (Q1 2026 slipped back to a small loss on seasonal patterns and reinvestment), and the company still carries a large accumulated deficit from its pre-commercial years, so results can stay volatile even as the top line compounds.

The dominant risk is single-product concentration: nearly all revenue depends on ZORYVE, so any slowdown in prescriptions, an unfavorable payer or pricing shift, a safety signal, or eventual generic and patent challenges would hit the whole company. Profitability is early and inconsistent, with Q1 2026 returning to a small loss on seasonality and reinvestment, and the business carries a large accumulated deficit built up over its pre-commercial years. Competition is real, including Incyte's Opzelura (a JAK-inhibitor cream), Dermavant's Vtama (tapinarof), generic topical steroids, and systemic biologics like Dupixent in atopic dermatitis. Gross-to-net adjustments, rebates, and inventory timing can make quarterly revenue lumpy, and continued sales-force and marketing spend can keep operating results volatile even as demand grows.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Arcutis Biotherapeutics, Inc.'s investor relations page or your broker.

• ZORYVE net sales (FY2025): ~$372 million (+123% YoY)
• 2026 revenue guidance: ~$480-495 million
• Q4 2025 revenue: ~$128 million (+84% YoY)
• Q4 2025 net income: ~$17 million (first profitable quarter)
• FY2025 net loss: ~$16 million
• Cash and investments: ~$200 million
• Market cap: ~$3 billion

As of MAY 2026, Arcutis trades as a high-growth, single-franchise dermatology name rather than a stable earner, so its valuation leans on ZORYVE's revenue trajectory and the durability of its early profitability. With a market cap near $3 billion against roughly $372 million of 2025 sales, the price-to-sales multiple reflects growth expectations, and the stock is sensitive to any change in prescription momentum or guidance. Because full-year GAAP profitability is not yet consistent, trailing P/E is not a meaningful anchor.

There are three common ways to get ARQT exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic basket, so ARQT sits alongside other stocks that express the same thesis.

Walnut takes the basket route. Describe a thesis where ARQT fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

Arcutis is a single-product dermatology growth story where ZORYVE's rapid, multi-indication expansion is pushing the company toward sustained profitability, so the stock tends to trade on prescription trends and label expansions rather than on a diversified earnings base.

Whether ARQT is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is ARQT a buy?, and where the stock could go from here in the ARQT stock forecast.

For income investors, whether ARQT pays a dividend and how the payout looks is covered in does ARQT pay a dividend?